High_JJ Incidence_NN of_IN Cefoxitin_NP and_CC Clindamycin_NP Resistance_NP among_IN Anaerobes_NP in_IN Taiwan_NP Susceptibilities_NP to_TO 16_CD antimicrobial_JJ agents_NNS were_VBD determined_VBN by_IN measurement_NN of_IN MICs_NP for_IN 344_CD isolates_NNS of_IN anaerobic_JJ bacteria_NNS recovered_VBN from_IN patients_NNS with_IN significant_JJ infections_NNS ._SENT Resistance_NN rates_NNS varied_VBN among_IN antimicrobial_JJ agents_NNS and_CC the_DT species_NNS tested_VBD ._SENT The_DT beta-lactams_NNS were_VBD more_RBR active_JJ in_IN gram-positive_NN than_IN in_IN gram-negative_JJ anaerobes_NNS ._SENT Resistance_NN to_TO meropenem_NN was_VBD low_JJ (_( <1_JJ %_NN )_) ._SENT For_IN beta-lactam-beta-lactamase_NN inhibitors_NNS ,_, piperacillin-tazobactam_NN was_VBD most_RBS active_JJ for_IN all_DT species_NNS (_( resistance_NN ,_, <6_JJ %_NN )_) ._SENT The_DT rates_NNS of_IN resistance_NN to_TO cefoxitin_NN (_( 31_CD to_TO 65_CD %_NN )_) and_CC clindamycin_NN (_( 50_CD to_TO 70_CD %_NN )_) for_IN non-Bacteroidesfragilis_NN species_NNS of_IN the_DT B._NP fragilis_NN group_NN were_VBD higher_JJR than_IN those_DT for_IN B._NP fragilis_NNS (_( 4_CD %_NN resistant_JJ to_TO cefoxitin_NN and_CC 33_CD %_NN resistant_JJ to_TO clindamycin_NN )_) ._SENT Among_IN members_NNS of_IN B._NP fragilis_NN group_NN ,_, Bacteroides_NP thetaiotaomicron_NP was_VBD the_DT most_RBS resistant_JJ to_TO clindamycin_NN (_( 70_CD %_NN )_) and_CC cefoxitin_NN (_( 65_CD %_NN )_) ._SENT Rates_NNS of_IN susceptibility_NN to_TO imipenem_NN and_CC metronidazole_NN for_IN B._NP fragilis_NNS continue_VBP to_TO be_VB high_RB compared_VBN to_TO those_DT from_IN a_DT previous_JJ study_NN 10_CD years_NNS ago_RB ._SENT However_RB ,_, resistance_NN to_TO metronidazole_NN was_VBD found_VBN recently_RB in_IN five_CD strains_NNS of_IN B._NP fragilis_NNS ._SENT We_PP analyzed_VBD the_DT genetic_JJ relationships_NNS among_IN the_DT metronidazole-resistant_JJ B._NP fragilis_NN strains_NNS by_IN pulsed-field_JJ gel_NN electrophoresis_NN ._SENT The_DT metronidazole-resistant_JJ B._NP fragilis_NN strains_NNS showed_VBD genotypic_JJ heterogeneity_NN ,_, excluding_VBG the_DT dissemination_NN of_IN a_DT single_JJ clone_NN ._SENT Over_IN the_DT past_JJ 10_CD years_NNS ,_, there_EX has_VBZ been_VBN a_DT significant_JJ problem_NN with_IN increasing_VBG resistance_NN to_TO antimicrobial_JJ agents_NNS among_IN anaerobic_JJ bacteria_NNS (_( -_: ,_, -_: )_) ._SENT Antimicrobial_JJ resistance_NN is_VBZ becoming_VBG less_RBR predictable_JJ and_CC may_MD fluctuate_VB from_IN one_CD medical_JJ center_NN to_TO another_DT ,_, as_RB well_RB as_RB from_IN one_CD geographic_JJ region_NN to_TO another_DT (_( -_: ,_, -_: )_) ._SENT The_DT increasing_VBG resistance_NN among_IN several_JJ species_NN emphasizes_VBZ the_DT need_NN to_TO survey_VB the_DT susceptibility_NN patterns_NNS of_IN these_DT organisms_NNS ._SENT Data_NNS on_IN susceptibilities_NNS of_IN anaerobes_NNS are_VBP very_RB limited_VBN in_IN Taiwan_NP except_IN those_DT from_IN a_DT previous_JJ report_NN of_IN 10_CD years_NNS ago_RB ._SENT The_DT objective_NN of_IN this_DT study_NN was_VBD to_TO determine_VB the_DT susceptibility_NN profiles_NNS of_IN clinical_JJ isolates_NNS of_IN anaerobes_NNS in_IN Taiwan_NP and_CC to_TO monitor_VB susceptibility_NN changes_NNS over_IN time_NN ._SENT Organisms_NNS tested_VBD included_VBN gram-positive_JJ and_CC gram-negative_JJ anaerobes_NNS which_WDT were_VBD clinically_RB commonly_RB encountered_VBN ._SENT The_DT test_NN antimicrobial_NN agents_NNS included_VBD old_JJ and_CC new_JJ agents_NNS ._SENT Among_IN the_DT older_JJR agents_NNS ,_, clindamycin_NN ,_, cefoxitin_NN ,_, and_CC piperacillin_NN are_VBP commonly_RB used_VBN as_IN the_DT initial_JJ empirical_JJ treatment_NN for_IN B._NP fragilis_NP group_NN infections_NNS ._SENT However_RB ,_, resistance_NN to_TO these_DT agents_NNS has_VBZ been_VBN shown_VBN to_TO increase_VB in_IN North_NP America_NP ,_, Europe_NP ,_, and_CC other_JJ countries_NNS during_IN the_DT past_JJ decades_NNS (_( -_: ,_, -_: ,_, )_) ._SENT The_DT 5-nitroimidazole_JJ molecules_NNS are_VBP very_RB potent_JJ anaerobicidal_JJ agents_NNS commonly_RB used_VBN to_TO treat_VB or_CC prevent_VB Bacteroides_NP infections_NNS ._SENT Although_IN resistance_NN to_TO metronidazole_NN in_IN Bacteroides_NP fragilis_NP strains_NNS has_VBZ been_VBN reported_VBN in_IN several_JJ countries_NNS ,_, resistance_NN to_TO metronidazole_NN in_IN B._NP fragilis_NP strains_NNS has_VBZ not_RB been_VBN reported_VBN in_IN Taiwan_NP before_RB ._SENT The_DT emergence_NN of_IN metronidazole-resistant_JJ B._NP fragilis_NN strains_NNS (_( MIC_NP ,_, >32_JJ mug/ml_NN )_) in_IN Taiwan_NP is_VBZ reported_VBN in_IN this_DT study_NN ._SENT Bacterial_JJ strains_NNS ._SENT |_SYM A_DT total_NN of_IN 344_CD clinical_JJ isolates_NNS of_IN anaerobes_NNS were_VBD collected_VBN between_IN 1998_CD and_CC 2000_CD from_IN the_DT Bacteriology_NP Laboratory_NP ,_, National_NP Taiwan_NP University_NP Hospital_NP ,_, a_DT 2,000-bed_JJ teaching_NN hospital_NN in_IN northern_JJ Taiwan_NP ._SENT These_DT isolates_NNS were_VBD recovered_VBN from_IN blood_NN ,_, pus_NN from_IN the_DT intra-abdominal_JJ cavity_NN ,_, abscesses_NNS ,_, soft_JJ tissue_NN ,_, head_NN or_CC neck_NN wounds_NNS ,_, and_CC others_NNS ._SENT Only_RB one_CD isolate_NN per_IN patient_NN was_VBD included_VBN ._SENT Antimicrobial_JJ susceptibility_NN testing_NN ._SENT |_SYM The_DT antimicrobial_JJ agents_NNS used_VBN for_IN susceptibility_NN testing_NN were_VBD as_RB follows_VBZ :_: penicillin_NN ,_, ampicillin_NP ,_, piperacillin_NP ,_, sulbactam_NP ,_, tazobactam_NP ,_, cefoperazone_NN ,_, clindamycin_NN ,_, chloramphenicol_NN ,_, and_CC metronidazole_NN (_( Sigma_NP Chemical_NP Co._NP ,_, St._NP Louis_NP ,_, Mo._NP )_) ;_: ticarcillin_NN and_CC clavulanic_JJ acid_NN (_( SmithKline_NP Beecham_NP ,_, Philadelphia_NP ,_, Pa._NP )_) ;_: cefoxitin_NN and_CC imipenem_NN (_( Merck_NP Sharp_NP &_CC Dohme_NP ,_, West_NP Point_NP ,_, Pa._NP )_) ;_: meropenem_NP (_( Sumitomo_NP Pharmaceuticals_NP ,_, Osaka_NP ,_, Japan_NP )_) ;_: cefmetazole_NP (_( Sankyo_NP ,_, Tokyo_NP ,_, Japan_NP )_) ;_: and_CC moxifloxacin_NP (_( Bayer_NP Corporation_NP ,_, West_NP Haven_NP ,_, Conn._NP )_) ._SENT Antimicrobial_JJ susceptibility_NN was_VBD tested_VBN by_IN an_DT agar_NN dilution_NN method_NN in_IN accordance_NN with_IN guidelines_NNS of_IN the_DT National_NP Committee_NP for_IN Clinical_NP Laboratory_NP Standards_NP (_( NCCLS_NP )_) ._SENT An_DT inoculum_NN of_IN 105_CD CFU_NP per_IN well_RB was_VBD applied_VBN with_IN a_DT Steers_NP replicator_NN onto_IN brucella_NN agar_NN supplemented_VBN with_IN vitamin_NN K1_NP and_CC 5_CD %_NN pooled_JJ sheep_NN blood_NN ._SENT Plates_NNS were_VBD incubated_VBN in_IN an_DT anaerobic_JJ chamber_NN for_IN 48_CD h_NN at_IN 35C_JJ ._SENT The_DT MIC_NN was_VBD defined_VBN as_IN the_DT concentration_NN at_IN which_WDT there_EX was_VBD a_DT marked_JJ change_NN in_IN the_DT appearance_NN of_IN growth_NN ,_, compared_VBN with_IN that_DT in_IN the_DT control_NN plate_NN ._SENT Reference_NN strains_NNS of_IN B._NP fragilis_NP ATCC_NP 25285_CD and_CC Bacteroides_NP thetaiotaomicron_NN ATCC_NP 29741_CD were_VBD used_VBN for_IN quality_NN control_NN of_IN the_DT susceptibility_NN tests_NNS ._SENT PFGE_NP ._SENT |_SYM Pulsed-field_NP gel_NN electrophoresis_NN (_( PFGE_NP )_) was_VBD performed_VBN to_TO genotype_NN five_CD metronidazole-resistant_JJ B._NP fragilis_NN strains_NNS ._SENT Each_DT strain_NN was_VBD grown_VBN overnight_RB at_IN 37C_JJ in_IN 10_CD ml_NN of_IN brain_NN heart_NN infusion_NN broth_NN in_IN an_DT anaerobic_JJ chamber_NN ._SENT The_DT preparation_NN of_IN DNA_NP was_VBD performed_VBN as_IN described_VBN previously_RB ._SENT After_IN appropriate_JJ preparation_NN ,_, the_DT DNAs_NP in_IN each_DT plug_NN were_VBD digested_VBN with_IN 20_CD U_NN of_IN XbaI_NP (_( New_NP England_NP Biolabs_NP ,_, Hitchin_NP ,_, United_NP Kingdom_NP )_) at_IN 37C_JJ for_IN 4_CD h._NN The_DT plugs_NNS were_VBD applied_VBN to_TO a_DT 1_CD %_NN agarose_NN gel_NN ._SENT Electrophoresis_NN was_VBD performed_VBN in_IN 0.5x_NP Tris-borate-EDTA_NP buffer_NN at_IN 14oC_NP by_IN using_VBG a_DT CHEF-DR_NP III_NP apparatus_NN (_( Bio-Rad_NP Laboratories_NP ,_, Hercules_NP ,_, Calif._NP )_) ,_, with_IN pulse_NN times_NNS ranging_VBG from_IN an_DT initial_JJ value_NN of_IN 4_CD s_NN to_TO a_DT final_JJ value_NN of_IN 30_CD s_NNS ,_, for_IN 16_CD h_NN at_IN 200_CD V._NP Antimicrobial_JJ susceptibilities_NNS ._SENT |_SYM The_DT MIC_JJ ranges_NNS ,_, MICs_NNS at_IN which_WDT 50_CD %_NN of_IN the_DT isolates_NNS were_VBD inhibited_VBN (_( MIC50s_NP )_) ,_, MICs_NP at_IN which_WDT 90_CD %_NN of_IN the_DT isolates_NNS were_VBD inhibited_VBN (_( MIC90s_NP )_) ,_, and_CC the_DT percentages_NNS of_IN 344_CD clinical_JJ isolates_NNS of_IN anaerobes_NNS that_WDT were_VBD susceptible_JJ ,_, intermediate_JJ ,_, or_CC resistant_JJ to_TO various_JJ antimicrobial_JJ agents_NNS are_VBP summarized_VBN in_IN Table_NP The_DT rates_NNS of_IN susceptible_JJ ,_, intermediate_JJ ,_, and_CC resistant_JJ isolates_NNS were_VBD determined_VBN by_IN using_VBG the_DT NCCLS_NP breakpoints_NNS ._SENT B._NP fragilis_NP group_NN isolates_NNS were_VBD the_DT most_RBS encountered_VBN clinically_RB significant_JJ isolates_NNS among_IN the_DT gram-negative_JJ anaerobes_NNS ._SENT The_DT B._NP fragilis_NN group_NN isolates_NNS were_VBD uniformly_RB resistant_JJ to_TO penicillin_NN and_CC ampicillin_NN ._SENT Most_JJS isolates_NNS were_VBD susceptible_JJ to_TO imipenem_NN or_CC meropenem_NN ._SENT Only_RB one_CD isolate_NN of_IN B._NP fragilis_NNS was_VBD found_VBN to_TO have_VB intermediate_JJ resistance_NN to_TO imipenem_NN ._SENT Comparison_NN of_IN the_DT susceptibilities_NNS of_IN the_DT individual_JJ species_NN of_IN the_DT B._NP fragilis_NN group_NN showed_VBD that_IN 40_CD %_NN of_IN B._NP fragilis_NP isolates_NNS were_VBD resistant_JJ to_TO piperacillin_NN ,_, 44_CD %_NN were_VBD resistant_JJ to_TO ticarcillin_NN ,_, and_CC 17_CD %_NN were_VBD resistant_JJ to_TO ampicillin-sulbactam_NN ._SENT Four_CD percent_NN of_IN B._NP fragilis_NP isolates_NNS were_VBD resistant_JJ to_TO cefoxitin_NN ;_: however_RB ,_, 22_CD %_NN had_VBD intermediate_JJ susceptibility_NN ._SENT Other_JJ members_NNS of_IN the_DT B._NP fragilis_NN group_NN were_VBD more_RBR resistant_JJ to_TO cefoxitin_NN ,_, with_IN resistance_NN rates_NNS between_IN 31_CD and_CC 65_CD %_NN ._SENT B._NP thetaiotaomicron_NP was_VBD the_DT species_NN with_IN the_DT greatest_JJS resistance_NN to_TO cefoxitin_NN (_( 65_CD %_NN )_) and_CC cefmetazole_NN (_( 80_CD %_NN )_) among_IN the_DT B._NP fragilis_NN group_NN ._SENT Resistance_NN to_TO clindamycin_NN varied_VBD among_IN the_DT species_NN from_IN 33_CD to_TO 70_CD %_NN ,_, with_IN the_DT highest_JJS resistance_NN rate_NN occurring_VBG in_IN B._NP thetaiotaomicron_NP (_( 70_CD %_NN )_) ,_, followed_VBN by_IN Bacteroides_NP caccae_NNS (_( 67_CD %_NN )_) ._SENT Chloramphenicol_NN and_CC metronidazole_NN were_VBD active_JJ against_IN >90_JJ %_NN of_IN isolates_NNS of_IN the_DT B._NP fragilis_NN group_NN ._SENT Only_RB 3_CD %_NN of_IN B._NP fragilis_NP isolates_NNS were_VBD resistant_JJ to_TO metronidazole_NN and_CC 2_CD %_NN were_VBD intermediately_RB resistant_JJ to_TO metronidazole_NN ._SENT All_DT Fusobacterium_NP isolates_NNS were_VBD susceptible_JJ to_TO ampicillin-sulbactam_NN ,_, ticarcillin-clavulanic_JJ acid_NN ,_, cefoxitin_NN ,_, and_CC imipenem_NN ._SENT The_DT majority_NN of_IN Fusobacterium_NP isolates_NNS (_( 95_CD %_NN )_) were_VBD susceptible_JJ to_TO cefmetazole_NN ._SENT Thirty-five_JJ percent_NN of_IN Fusobacterium_NP isolates_NNS were_VBD resistant_JJ to_TO clindamycin_NN ._SENT More_JJR than_IN half_NN of_IN Prevotella_NP species_NN isolates_NNS (_( 62_CD %_NN )_) were_VBD resistant_JJ to_TO penicillin_NN and_CC ampicillin_NN ._SENT Rates_NNS of_IN resistance_NN to_TO cefoxitin_NN ,_, cefmetazole_NN ,_, and_CC clindamycin_NN were_VBD 6_CD ,_, 12_CD ,_, and_CC 31_CD %_NN ,_, respectively_RB ._SENT All_DT of_IN the_DT Prevotella_NP isolates_NNS tested_VBD were_VBD susceptible_JJ to_TO imipenem_NN ,_, meropenem_NN ,_, and_CC chloramphenicol_NN ._SENT Among_IN Veillonella_NP isolates_NNS ,_, 70_CD %_NN were_VBD resistant_JJ to_TO penicillin_NN and_CC ampicillin_NN ._SENT Five_CD percent_NN of_IN Veillonella_NP isolates_NNS were_VBD resistant_JJ to_TO piperacillin_NN ,_, ticarcillin_NP ,_, piperacillin-tazobactam_NN ,_, and_CC ticarcillin-clavulanic_JJ acid_NN ._SENT Ten_CD percent_NN were_VBD resistant_JJ to_TO cefoxitin_NN ,_, 55_CD %_NN were_VBD resistant_JJ to_TO clindamycin_NN ,_, and_CC 20_CD %_NN were_VBD resistant_JJ to_TO metronidazole_NN ._SENT All_DT isolates_NNS were_VBD susceptible_JJ to_TO ampicillin-sulbactam_NN ,_, imipenem_NN ,_, meropenem_NN ,_, and_CC chloramphenicol_NN ._SENT Of_IN the_DT gram-positive_JJ isolates_NNS ,_, the_DT 20_CD Clostridium_NP perfringens_NNS isolates_NNS were_VBD susceptible_JJ to_TO all_DT of_IN the_DT agents_NNS tested_VBD ._SENT Other_JJ gram-positive_JJ anaerobes_NNS showed_VBD various_JJ degrees_NNS of_IN resistance_NN to_TO penicillin_NN (_( 12_CD to_TO 16_CD %_NN )_) and_CC ampicillin_NP (_( 13_CD to_TO 25_CD %_NN )_) ._SENT Among_IN Peptostreptococcus_NP species_NN isolates_NNS ,_, 16_CD %_NN were_VBD resistant_JJ to_TO penicillin_NN ._SENT All_DT isolates_NNS were_VBD susceptible_JJ to_TO piperacillin-tazobactam_NN and_CC meropenem_NN ._SENT Of_IN Peptostreptococcus_NP species_NN isolates_NNS ,_, 3_LS %_NN were_VBD resistant_JJ to_TO cefoxitin_NN and_CC imipenem_NN but_CC 55_CD %_NN were_VBD resistant_JJ to_TO clindamycin_NN ._SENT Clostridium_NN species_NNS other_JJ than_IN C._NP perfringens_NNS were_VBD more_RBR resistant_JJ than_IN C._NP perfringens_NNS ,_, with_IN 12_CD %_NN of_IN the_DT isolates_NNS resistant_JJ to_TO penicillin_NN and_CC ticarcillin_NN ,_, 25_CD %_NN resistant_JJ to_TO ampicillin_NN ,_, and_CC 31_CD %_NN resistant_JJ to_TO metronidazole_NN ._SENT The_DT MIC50s_NP and_CC MIC90s_NP of_IN moxifloxacin_NN for_IN all_DT species_NN ranged_VBD from_IN 0.12_CD to_TO 2_CD mug/ml_NN (_( MIC50s_NP )_) and_CC from_IN 0.25_CD to_TO 8_CD mug/ml_NN (_( MIC90s_NP )_) ._SENT Trend_NN of_IN cefoxitin_NN and_CC clindamycin_NN resistance_NN in_IN B._NP thetaiotaomicron_NN ._SENT |_SYM Figure_NN shows_VBZ the_DT annual_JJ rates_NNS of_IN susceptibility_NN to_TO six_CD routinely_RB tested_VBN agents_NNS for_IN all_DT of_IN the_DT Bacteroides_NP species_NN isolates_VBZ at_IN National_NP Taiwan_NP University_NP Hospital_NP from_IN 1977_CD to_TO 2000_CD ._SENT The_DT rates_NNS of_IN susceptibility_NN to_TO cefmetazole_NN and_CC clindamycin_NN decreased_VBD ._SENT Susceptibility_NN testing_NN was_VBD performed_VBN by_IN the_DT disk_NN diffusion_NN method_NN before_IN 1990_CD and_CC by_IN the_DT breakpoint_NN agar_NN dilution_NN method_NN after_IN 1991_CD ._SENT A_DT stepwise_JJ increase_NN in_IN the_DT rates_NNS of_IN resistance_NN to_TO cefoxitin_NN and_CC clindamycin_NN resistance_NN was_VBD noted_VBN ._SENT PFGE_NN of_IN metronidazole-resistant_JJ B._NP fragilis_NP isolates_VBZ ._SENT |_SYM Five_JJ metronidazole-resistant_JJ strains_NNS of_IN B._NP fragilis_NNS were_VBD found_VBN in_IN this_DT study_NN ._SENT Since_IN no_DT metronidazole-resistant_JJ strains_NNS of_IN B._NP fragilis_NNS were_VBD reported_VBN before_IN in_IN Taiwan_NP ._SENT We_PP analyzed_VBD the_DT genetic_JJ relationships_NNS among_IN these_DT strains_NNS by_IN PFGE_NP ._SENT The_DT results_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT Lanes_NNS 1_CD to_TO 6_CD show_NN metronidazole-nonsusceptible_JJ B._NP fragilis_NN isolates_NNS ;_: lanes_NNS 2_CD and_CC 3_CD show_NN isolates_NNS from_IN the_DT same_JJ individual_NN ._SENT Lanes_NNS 7_CD to_TO 9_CD show_NN metronidazole-susceptible_JJ B._NP fragilis_NP isolates_VBZ ._SENT Two_CD strains_NNS (_( lanes_NNS 2_CD or_CC 3_CD and_CC 4_CD )_) were_VBD similar_JJ ._SENT Other_JJ strains_NNS have_VBP distinct_JJ patterns_NNS ._SENT These_DT isolates_NNS showed_VBD genotypic_JJ heterogeneity_NN ,_, suggesting_VBG that_IN they_PP correspond_VBP to_TO a_DT highly_RB heterogeneous_JJ population_NN rather_RB than_IN to_TO the_DT dissemination_NN of_IN a_DT single_JJ clone_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Rates_NNS of_IN susceptibility_NN to_TO six_CD routinely_RB tested_VBN agents_NNS in_IN all_DT of_IN the_DT Bacteroides_NP species_NN isolates_VBZ at_IN National_NP Taiwan_NP University_NP Hospital_NP from_IN 1977_CD to_TO 2000_CD ._SENT Rates_NNS of_IN susceptibility_NN to_TO six_CD routinely_RB tested_VBN agents_NNS in_IN all_DT of_IN the_DT Bacteroides_NP species_NN isolates_VBZ at_IN National_NP Taiwan_NP University_NP Hospital_NP from_IN 1977_CD to_TO 2000_CD ._SENT Susceptibility_NN testing_NN was_VBD performed_VBN by_IN the_DT disk_NN diffusion_NN method_NN before_IN 1990_CD and_CC by_IN the_DT breakpoint_NN agar_NN dilution_NN method_NN after_IN 1991_CD ._SENT SAM_NP ,_, ampicillin-_NN sulbactam_NN ._SENT FIG._NN 2_CD ._SENT |_SYM PFGE_NP analysis_NN of_IN XbaI-digested_JJ genomic_JJ DNA_NN from_IN B._NP fragilis_NP PFGE_NP analysis_NN of_IN XbaI-digested_JJ genomic_JJ DNA_NN from_IN B._NP fragilis_NP isolates_VBZ ._SENT Lane_NP M_NP ,_, lambda_NN ladder_NN molecular_JJ size_NN markers_NNS ;_: lanes_NNS 1_CD to_TO 6_CD ,_, metronidazole-nonsusceptible_JJ B._NP fragilis_NN isolates_VBZ (_( lanes_NNS 2_CD and_CC 3_CD ,_, isolates_VBZ from_IN the_DT same_JJ individual_NN )_) ;_: lanes_NNS 7_CD to_TO 9_CD ,_, metronidazole-susceptible_JJ B._NP fragilis_NP isolates_VBZ ._SENT TABLE_NN 1_CD |_SYM In_IN vitro_NN susceptibilities_NNS of_IN clinical_JJ isolates_NNS of_IN anaerobes_NNS In_IN this_DT study_NN the_DT antimicrobial_JJ susceptibilities_NNS of_IN 344_CD isolates_NNS of_IN anaerobes_NNS to_TO various_JJ agents_NNS were_VBD determined_VBN ._SENT In_IN agreement_NN with_IN other_JJ reports_NNS ,_, the_DT susceptibility_NN results_NNS varied_VBN among_IN genera_NNS and_CC species_NNS ._SENT Compared_VBN to_TO a_DT previous_JJ study_NN by_IN our_PP$ group_NN of_IN 100_CD B._NP fragilis_NN isolates_VBZ done_VBN 10_CD years_NNS ago_RB ,_, the_DT increased_VBN resistance_NN of_IN the_DT B._NP fragilis_NN group_NN to_TO cefoxitin_NN and_CC clindamycin_NN is_VBZ noted_VBN ._SENT Rates_NNS of_IN resistance_NN to_TO cefoxitin_NN for_IN B._NP fragilis_NNS increased_VBD from_IN 1_CD to_TO 4_CD %_NN and_CC rates_NNS of_IN resistance_NN to_TO clindamycin_NN increased_VBD from_IN 29_CD to_TO 33_CD %_NN over_IN the_DT period_NN from_IN 1991_CD to_TO 2000_CD ._SENT The_DT level_NN of_IN chloramphenicol_NN susceptibility_NN remained_VBD unchanged_JJ ._SENT As_IN expected_VBN ,_, the_DT beta-lactams_NNS were_VBD more_RBR active_JJ in_IN gram-positive_NN than_IN in_IN gram-negative_JJ anaerobes_NNS ._SENT According_VBG to_TO NCCLS_NP guidelines_NNS ,_, members_NNS of_IN the_DT B._NP fragilis_NN group_NN are_VBP presumed_VBN to_TO be_VB resistant_JJ to_TO ampicillin_NN ._SENT Peptostreptococcus_NP species_NNS have_VBP been_VBN considered_VBN fully_RB susceptible_JJ to_TO several_JJ beta-lactam_NN drugs_NNS ,_, including_VBG penicillin_NN G._NP In_IN the_DT present_JJ study_NN ,_, isolates_VBZ resistant_JJ to_TO penicillin_NN within_IN Peptostreptococcus_NP species_NNS were_VBD mostly_RB Peptostreptococcus_NP anaerobius_NP ._SENT In_IN Korea_NP ,_, the_DT rate_NN of_IN resistance_NN to_TO penicillin_NN of_IN P._NP anaerobius_NP was_VBD also_RB high_JJ ,_, while_IN those_DT of_IN other_JJ species_NNS were_VBD lower_JJR ._SENT Addition_NN of_IN a_DT beta-lactamase_NN inhibitor_NN generally_RB reversed_VBD the_DT resistance_NN ._SENT However_RB ,_, Veillonella_NP displayed_VBD similar_JJ susceptibilities_NNS to_TO piperacillin_NN and_CC piperacillin-tazobactam_NN and_CC ticarcillin_NN and_CC ticarcillin-clavulanic_JJ acid_NN ._SENT The_DT rate_NN of_IN resistance_NN to_TO ampicillin-sulbactam_NN in_IN B._NP fragilis_NN isolates_NNS increased_VBN from_IN 8_CD (_( 1991_CD )_) to_TO 17_CD %_NN (_( this_DT study_NN )_) ._SENT Resistance_NN to_TO piperacillin-tazobactam_NN was_VBD low_JJ (_( <6_JJ %_NN )_) ._SENT Data_NNS collected_VBN from_IN our_PP$ hospital_NN 's_POS clinical_JJ microbiology_NN laboratory_NN reveal_VBP the_DT decrease_NN in_IN susceptibility_NN to_TO cefmetazole_NN in_IN Bacteroides_NP species_NNS from_IN 1987_CD to_TO 2000_CD ._SENT Cefoxitin_NP was_VBD more_RBR active_JJ than_IN cefmetazole_NN against_IN most_JJS species_NNS ._SENT Rates_NNS of_IN resistance_NN to_TO cefoxitin_NN varied_VBD greatly_RB with_IN species_NNS and_CC country_NN ._SENT In_IN our_PP$ institution_NN ,_, the_DT percentage_NN of_IN resistance_NN to_TO cefoxitin_NN rose_VBD from_IN 1_CD %_NN in_IN 1991_CD to_TO 4_CD %_NN for_IN B._NP fragilis_NP and_CC from_IN 10_CD to_TO 70_CD %_NN for_IN B._NP thetaiotaomicron_NN ._SENT The_DT rate_NN of_IN resistance_NN to_TO cefoxitin_NN among_IN the_DT B._NP fragilis_NN group_NN was_VBD 12.8_CD %_NN in_IN Spain_NP ,_, 11.3_CD %_NN in_IN Canada_NP (_( 1997_CD )_) ,_, and_CC 1.7_CD to_TO 14.2_CD %_NN depending_VBG on_IN the_DT species_NN in_IN the_DT United_NP States_NPS (_( 1995_CD and_CC 1996_CD )_) ,_, 2.9_CD to_TO 34.5_CD %_NN in_IN Japan_NP (_( 1990_CD to_TO 1992_CD )_) ,_, and_CC 5_CD %_NN in_IN South_NP Africa_NP ._SENT MICs_NNS for_IN many_JJ isolates_NNS were_VBD 32_CD mug/ml_NN ,_, which_WDT was_VBD considered_VBN by_IN the_DT NCCLS_NP as_IN intermediate_JJ in_IN susceptibility_NN ._SENT Fusobacterium_NN isolates_NNS remained_VBD susceptible_JJ to_TO cefoxitin_NN ._SENT The_DT high_JJ rates_NNS of_IN resistance_NN to_TO cefoxitin_NN in_IN non-B_NN ._SENT fragilis_NP Bacteroides_NP species_NNS were_VBD unusual_JJ ._SENT The_DT use_NN of_IN cefoxitin_NN and_CC cefmetazole_NN has_VBZ not_RB increased_VBN in_IN the_DT past_JJ 10_CD years_NNS ._SENT Therefore_RB the_DT reason_NN for_IN the_DT high_JJ incidence_NN of_IN resistance_NN to_TO cefoxitin_NN is_VBZ unclear_JJ ._SENT For_IN all_DT species_NN ,_, high_JJ rates_NNS of_IN susceptibility_NN to_TO imipenem_NN and_CC meropenem_NN were_VBD observed_VBN ._SENT Resistance_NN to_TO meropenem_NN was_VBD low_JJ (_( <1_JJ %_NN )_) ._SENT One_CD isolate_NN of_IN B._NP fragilis_NP and_CC one_CD isolate_NN of_IN Peptostreptococcus_NP displayed_VBD intermediate_JJ susceptibility_NN ,_, and_CC another_DT Peptostreptococcus_NP isolate_NN displayed_VBD resistance_NN ,_, to_TO imipenem_NN ._SENT In_IN general_NN ,_, The_DT MIC90s_NP of_IN imipenem_NN and_CC meropenem_NN were_VBD similar_JJ except_IN that_IN some_DT isolates_NNS showed_VBD discordant_JJ susceptibilities_NNS to_TO imipenem_NN and_CC meropenem_NN ._SENT For_IN example_NN ,_, six_CD isolates_NNS of_IN B._NP fragilis_NNS (_( five_CD intermediate_NN and_CC one_CD resistant_NN )_) were_VBD not_RB susceptible_JJ to_TO meropenem_NN ,_, but_CC only_RB one_CD isolate_NN was_VBD not_RB susceptible_JJ to_TO imipenem_NN ._SENT Eight_CD percent_NN of_IN B._NP thetaiotaomicron_NN isolates_NNS were_VBD resistant_JJ to_TO imipenem_NN but_CC susceptible_JJ to_TO meropenem_NN ._SENT Compared_VBN to_TO the_DT data_NNS of_IN our_PP$ previous_JJ report_NN ,_, the_DT rate_NN of_IN resistance_NN to_TO imipenem_NN for_IN B._NP fragilis_NP has_VBZ not_RB increased_VBN ,_, but_CC the_DT MIC50_NP (_( from_IN 0.12_CD to_TO 0.5_CD mug/ml_NN )_) and_CC MIC90_NP (_( from_IN 1_CD to_TO 4_CD mug/ml_NN )_) have_VBP increased_VBN slightly_RB ._SENT Resistance_NN to_TO the_DT carbapenems_NNS has_VBZ been_VBN occasionally_RB and_CC infrequently_RB recorded_VBN ._SENT Clindamycin_NN has_VBZ long_RB been_VBN considered_VBN the_DT drug_NN of_IN choice_NN for_IN treatment_NN of_IN anaerobes_NNS ._SENT However_RB ,_, over_IN the_DT past_JJ 20_CD years_NNS ,_, there_EX has_VBZ been_VBN a_DT significant_JJ increase_NN in_IN the_DT rate_NN of_IN resistance_NN to_TO clindamycin_NN among_IN isolates_NNS of_IN the_DT B._NP fragilis_NN group_NN in_IN many_JJ areas_NNS (_( ,_, ,_, ,_, -_: )_) ._SENT In_IN our_PP$ institution_NN ,_, the_DT overall_JJ activities_NNS of_IN clindamycin_NN against_IN the_DT B._NP fragilis_NN group_NN were_VBD poor_JJ (_( 33_CD to_TO 70_CD %_NN )_) ._SENT The_DT high_JJ prevalence_NN of_IN resistance_NN to_TO clindamycin_NN in_IN B._NP fragilis_NP group_NN isolates_NNS has_VBZ been_VBN described_VBN previously_RB in_IN several_JJ reports_NNS ._SENT For_IN example_NN ,_, a_DT high_JJ prevalence_NN of_IN resistance_NN to_TO clindamycin_NN (_( 49_CD %_NN )_) in_IN the_DT B._NP fragilis_NN group_NN was_VBD observed_VBN by_IN Betriu_NP et_FW al._FW in_IN Spain_NP ._SENT In_IN Korea_NP ,_, in_IN 1994_CD ,_, the_DT rates_NNS of_IN resistance_NN to_TO clindamycin_NN for_IN B._NP fragilis_NP ,_, B._NP thetaiotaomicron_NP ,_, and_CC other_JJ Bacteroides_NP spp._NP were_VBD 38_CD ,_, 45.5_CD ,_, and_CC 69_CD %_NN ,_, respectively_RB ._SENT However_RB ,_, in_IN several_JJ areas_NNS the_DT rate_NN of_IN resistance_NN to_TO clindamycin_NN for_IN the_DT B._NP fragilis_NN group_NN remained_VBD low_JJ ._SENT In_IN South_NP Africa_NP ,_, only_RB 5_CD %_NN of_IN isolates_NNS were_VBD resistant_JJ to_TO clindamycin_NN in_IN the_DT B._NP fragilis_NN group_NN ._SENT It_PP was_VBD also_RB reported_VBN that_IN clindamycin_NN resistance_NN is_VBZ associated_VBN with_IN hospital-acquired_JJ infections_NNS ._SENT Rates_NNS of_IN resistance_NN for_IN isolates_NNS varied_VBN greatly_RB with_IN species_NNS and_CC country_NN ._SENT In_IN the_DT present_JJ study_NN ,_, high_JJ rates_NNS of_IN resistance_NN to_TO clindamycin_NN were_VBD found_VBN for_IN the_DT following_VBG organisms_NNS :_: B._NP thetaiotaomicron_NP (_( 70_CD %_NN )_) ,_, B._NP caccae_NNS (_( 67_CD %_NN )_) ,_, Bacteroides_NP uniformis_NNS (_( 56_CD %_NN )_) ,_, Veillonella_NP and_CC Peptostreptococcus_NP spp._NP (_( 55_CD %_NN )_) ,_, Fusobacterium_NP spp._NP (_( 35_CD %_NN )_) ,_, and_CC B._NP fragilis_NP and_CC Prevotella_NP spp._NP (_( 31_CD %_NN )_) ._SENT B._NP thetaiotaomicron_NP isolates_NNS were_VBD also_RB more_RBR resistant_JJ to_TO cefoxitin_NN than_IN other_JJ species_NNS ._SENT In_IN agreement_NN with_IN other_JJ reports_NNS ,_, the_DT resistance_NN rates_NNS for_IN non-B_NN ._SENT fragilis_NN species_NNS of_IN the_DT B._NP fragilis_NN group_NN were_VBD found_VBN higher_JJR than_IN that_DT for_IN B._NP fragilis_NNS (_( 33_CD %_NN )_) ._SENT Aldridge_NP et_FW al._FW reported_VBD that_IN Bacteroides_NP distasonis_NP and_CC Bacteroides_NP ovatus_NN were_VBD more_RBR resistant_JJ to_TO clindamycin_NN than_IN other_JJ species_NNS ._SENT Since_IN B._NP thetaiotaomicron_NN is_VBZ usually_RB the_DT second_JJ most_RBS frequently_RB encountered_VBN Bacteroides_NP species_NNS ,_, rapid_JJ detection_NN and_CC identification_NN are_VBP important_JJ ._SENT We_PP recently_RB described_VBD a_DT PCR_NP assay_NN which_WDT provided_VBD a_DT rapid_JJ and_CC accurate_JJ method_NN for_IN identification_NN of_IN B._NP thetaiotaomicron_NN ._SENT Among_IN gram-positive_JJ anaerobes_NNS ,_, C._NP perfringens_NNS was_VBD the_DT most_RBS susceptible_JJ ._SENT Other_JJ Clostridium_NN species_NNS were_VBD less_RBR susceptible_JJ to_TO penicillin_NN ,_, ampicillin_NP ,_, ticarcillin_NN ,_, and_CC metronidazole_NN ._SENT This_DT result_NN is_VBZ similar_JJ to_TO the_DT finding_NN of_IN a_DT study_NN done_VBN in_IN Korea_NP but_CC is_VBZ different_JJ from_IN that_DT of_IN a_DT study_NN done_VBN in_IN South_NP Africa_NP ._SENT In_IN the_DT present_JJ study_NN ,_, the_DT MIC_JJ results_NNS for_IN moxifloxacin_NN confirm_VBP the_DT broad_JJ spectrum_NN of_IN its_PP$ activity_NN against_IN gram-positive_JJ and_CC gram-negative_JJ anaerobic_JJ bacteria_NNS ._SENT Although_IN no_DT interpretation_NN standard_NN is_VBZ available_JJ for_IN anaerobes_NNS ,_, for_IN the_DT anaerobic_JJ bacteria_NNS tested_VBN ,_, the_DT moxifloxacin_NP MIC50_NP varied_VBD from_IN 0.12_CD to_TO 2_CD mug/ml_NN and_CC MIC90_NP varied_VBD from_IN 0.25_CD to_TO 8_CD mug/ml_NN ._SENT Many_JJ new_JJ fluoroquinolones_NNS have_VBP been_VBN tested_VBN for_IN in_IN vitro_NN activities_NNS against_IN gram-positive_JJ ,_, gram-negative_JJ ,_, and_CC anaerobic_JJ bacteria_NNS previously_RB ._SENT Similarly_RB ,_, other_JJ studies_NNS have_VBP demonstrated_VBN the_DT good_JJ activity_NN of_IN new_JJ fluoroquinolones_NNS against_IN various_JJ anaerobic_JJ species_NNS ._SENT Moxifloxacin_NN is_VBZ ,_, therefore_RB ,_, a_DT potentially_RB useful_JJ antibiotic_NN against_IN anaerobes_NNS ._SENT The_DT rates_NNS of_IN resistance_NN to_TO metronidazole_NN for_IN several_JJ gram-positive_JJ anaerobes_NNS ,_, Peptostreptococcus_NP (_( 32_CD %_NN )_) and_CC Clostridium_NP species_NNS (_( 31_CD %_NN )_) other_JJ than_IN C._NP perfringens_NNS ,_, were_VBD higher_JJR than_IN those_DT for_IN gram-negative_JJ anaerobes_NNS Fusobacterium_NN (_( 25_CD %_NN )_) ,_, Veillonella_NP (_( 20_CD %_NN )_) ,_, Prevotella_NP (_( 13_CD %_NN )_) ,_, and_CC Bacteroides_NP species_NNS (_( <3_JJ %_NN )_) ._SENT Previous_JJ reports_NNS also_RB showed_VBD that_IN peptostreptococci_NNS are_VBP generally_RB less_RBR susceptible_JJ to_TO metronidazole_NN than_IN gram-negative_JJ anaerobes_NNS ._SENT A_DT similar_JJ percentage_NN of_IN resistance_NN to_TO metronidazole_NN for_IN peptostreptococci_NNS in_IN Korea_NP was_VBD described_VBN by_IN Lee_NP et_FW al._FW ._SENT Resistance_NN to_TO metronidazole_NN among_IN B._NP fragilis_NP isolates_VBZ in_IN Taiwan_NP is_VBZ first_RB documented_VBN in_IN this_DT report_NN ._SENT By_IN PFGE_NP analysis_NN ,_, five_CD strains_NNS (_( four_CD patterns_NNS )_) showed_VBD genotypic_JJ heterogeneity_NN ,_, suggesting_VBG that_IN they_PP correspond_VBP to_TO a_DT heterogeneous_JJ population_NN rather_RB than_IN to_TO the_DT dissemination_NN of_IN a_DT single_JJ clone_NN ._SENT The_DT results_NNS suggest_VBP that_IN the_DT emergence_NN of_IN these_DT resistant_JJ strains_NNS may_MD be_VB sporadic_JJ ._SENT The_DT development_NN of_IN antibiotic_JJ resistance_NN in_IN anaerobic_JJ bacteria_NNS has_VBZ a_DT tremendous_JJ impact_NN on_IN the_DT selection_NN of_IN antimicrobial_JJ agents_NNS for_IN empirical_JJ therapy_NN ._SENT It_PP suggests_VBZ the_DT need_NN to_TO monitor_VB antibiotic_JJ susceptibility_NN patterns_NNS of_IN anaerobes_NNS related_VBN to_TO geographic_JJ regions_NNS periodically_RB ._SENT 